Keywords: gsk, elects, exercise, xl784, option, uk, drug

GSK elects not to exercise XL784 option

Article | 28 January 2008

Print This

UK drug major GlaxoSmithKline has decided not to exercise its option to license the candidate diabetic nephropathy drug XL784 from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in